Klin Farmakol Farm. 2018;32(1):14-19 | DOI: 10.36290/far.2018.003

Drug-induced nephropathy

Markéta Kolečková, Tomáš Tichý
Ústav klinické a molekulární patologie, Univerzita Palackého a FN Olomouc

The kidneys are a frequent target of both acute and chronic drug-induced injury because of their concentration and eliminationfunction. However, mechanisms of their nephrotoxicity vary in dependence on the drug group. Histological verification,along with a history of pharmacological therapy, is still regarded as a gold standard of diagnostic process. From a pathologicalpoint of view, all the structures of the renal parenchyma may be involved. In the majority of cases the involvement of renaltubules and interstitium is observed, characterized by the image of ischemic and nephrotoxic acute tubular necrosis, acuteor chronic tubulointerstitial nephritis with possible transition to end-stage renal disease. In a smaller number of cases we canidentify the immune-mediated glomerulopathies, direct cell injury glomerulopathies, vascular lesions, osmotic nephrosisassociated with hypertonic solution application or crystalline nephropathy. The aim of our article is to provide an overviewof pathology and pathogenesis of renal impairment in relation to individual drug groups. The proper knowledge of these mechanismstogether with preventive approaches is in charge of patient’s prognosis in terms of renal function recovery.

Keywords: kidney, renal impairment, drug-induced kidney injury, adverse drug reaction, histological features

Published: May 31, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolečková M, Tichý T. Drug-induced nephropathy. Klin Farmakol Farm. 2018;32(1):14-19. doi: 10.36290/far.2018.003.
Download citation

References

  1. Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015; 41(8): 1411-1423. Go to original source... Go to PubMed...
  2. Uchino S. The epidemiology of acute renal failure in the world. Curr Opin Crit Care. 2006; 12(6): 538-543. Go to original source... Go to PubMed...
  3. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005; 294(7): 813-818. Go to original source... Go to PubMed...
  4. Dobrucká K. Polékové poškození ledvin. Prakt. lékáren. 2014; 10(4): 137-141.
  5. Tisdale JE, Miller DA. Drug induced diseases. Prevention, Detection, and Management, 2nd Edition In: Drug-Induced Diseases of the Kidney & Fluid & Electrolyte Disorders. 2010, American Society of Health-System Pharmacists, Inc., 853-872. ISBN: 978-58528-205-0.
  6. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. Kidney Int 2012; Suppl. 2: 1-138.
  7. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017; 92(1): 26-36. Go to original source... Go to PubMed...
  8. Mercadal L, Franck JE, Metzger M, et al. REIN Registry. Hemodiafiltration Versus Hemodialysis and Survival in Patients With ESRD: The French Renal Epidemiology and Information Network (REIN) Registry. Am J Kidney Dis. 2016. Go to original source... Go to PubMed...
  9. Stengel B, Couchoud C. Chronic Kidney Disease Prevalence and Treated End-Stage Renal Disease Incidence: A Complex Relationship. 2015; 68(2): 247-255.
  10. De Nicola L, Donfrancesco C, Minutolo R, et al. ANMCO-SIN Research Group. Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008-12 National Health Examination Survey. Nephrol Dial Transplant. 2015; 30(5): 806-814. Go to original source... Go to PubMed...
  11. Croes S, Koop AH, van Gils SA, et al. Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring. Eur J Pharm Sci. 2012; 45(1-2): 90-100. Go to original source... Go to PubMed...
  12. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med. 2008; 36(4 Suppl): S216-223. Go to original source... Go to PubMed...
  13. Filippone EJ, Kraft WK, Farber JL. The Nephrotoxicity of Vancomycin. Clin Pharmacol Ther. 2017; 102(3): 459-469. Go to original source... Go to PubMed...
  14. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006; 166(19): 2138-2144. Go to original source... Go to PubMed...
  15. Tonin FS, Steimbach LM, Borba HH, et al. Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis. J Pharm Pharmacol. 2017 Aug 17. doi: 10.1111/jphp.12802. [Epub ahead of print] Go to original source... Go to PubMed...
  16. Svoboda L. Poškození ledvin kontrastní látkou. Med. Pro Praxi 2007; 4(10): 410-415.
  17. Kiss N, Hamar P. Histopathological Evaluation of Contrast-Induced Acute Kidney Injury Rodent Models. Biomed Res Int. 2016; 2016: 3763250. Epub 2016 Nov 16. Go to original source... Go to PubMed...
  18. Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, et al. Contrast-induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies. Pharmacol Ther. 2017 Jun 19. pii: S0163-7258(17)30157-2. doi: 10.1016/j.pharmthera.2017.06.009. [Epub ahead of print]. Go to original source... Go to PubMed...
  19. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999; 106(5B): 13S-24S. Go to original source... Go to PubMed...
  20. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum. 2002; 32(3 Suppl 1): 33-42. Go to original source... Go to PubMed...
  21. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med. 2000; 133(1): 1-9. Go to original source... Go to PubMed...
  22. Mathis AS, Egloff G, Ghin HL. Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies. World J Transplant. 2014; 4(2): 57-80. Go to original source... Go to PubMed...
  23. Tanabe K. Calcineurin inhibitors in renal transplantation: what is the best option? Drugs. 2003; 63(15): 1535-1548. Go to original source... Go to PubMed...
  24. Morales JM, Andres A, Rengel M, et al. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. ephrol Dial Transplant. 2001; 16 Suppl 1: 121-124. Go to original source... Go to PubMed...
  25. Paueksakon P, Fogo AB. Drug-induced nephropathies. Histopathology. 2017; 70(1): 94-108. Go to original source... Go to PubMed...
  26. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001; 60(2): 804-817. Go to original source... Go to PubMed...
  27. Heap GA, So K, Weedon M, et al. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis. 2016; 10(2): 149-158. Go to original source... Go to PubMed...
  28. Van Staa TP, Travis S, Leufkens HGM, et al. 5-Aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 2004; 126: 1733-1739. Go to original source... Go to PubMed...
  29. Arif F. Nephrotoxic potential of proton pump inhibitors. Eur J Intern Med. 2017; 42: e16 Go to original source... Go to PubMed...
  30. Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015; 3(2): E166-171. Go to original source... Go to PubMed...
  31. Pinheiro LC, Oliveira-Paula GH, Portella RL, et al. Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction. Redox Biol. 2016; 9: 134-143. Go to original source... Go to PubMed...
  32. De Vriese AS, Robbrecht DL, Vanholder RC, et al. Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. Am J Kidney Dis. 1998; 31(1): 108-115. Go to original source... Go to PubMed...
  33. Chiba S, Tsuchiya K, Sakashita H, et al. Rifampicin-induced acute kidney injury during the initial treatment for pulmonary tuberculosis: a case report and literature review. Intern Med. 2013; 52(21): 2457-2460. Go to original source... Go to PubMed...
  34. Manika K, Tasiopoulou K, Vlogiaris L, et al. Rifampicin-associated acute renal failure and hemolysis: a rather uncommon but severe complication. Ren Fail. 2013; 35(8): 1179-1181. Go to original source... Go to PubMed...
  35. Amsler E, Soria A. Hypersensitivity reactions to beta-lactam antibiotics. Rev Med Interne. 2017 Jul 25. doi: 10.1016/j.revmed.2017.06.020. [Epub ahead of print] Go to original source... Go to PubMed...
  36. Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med. 2009; 122(4): 322-328. Go to original source... Go to PubMed...
  37. Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost. 2005; 31(6): 681-690. Go to original source... Go to PubMed...
  38. Khurana R, Deswal S, Prakash C, et al. Cisplatin Induced Renal Insufficiency Measured by Glomerular Filtration Rate with 99mTc-DTPA and by using Serum Creatinine based Formulae: A Prospective Study. J Clin Diagn Res. 2016; 10(12): XC05-XC07. Go to original source... Go to PubMed...
  39. Nematbakhsh M, Pezeshki Z, Eshraghi JF, et al. Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences Asian Pac J Cancer Prev. 2017; 18(2): 295-314. Go to PubMed...
  40. Simon TP, Schuerholz T, Hüter L, et al. Impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study. Crit Care. 2012; 16(1): R16. Go to original source... Go to PubMed...
  41. Nomani AZ, Nabi Z, Rashid H, et al. Osmotic nephrosis with mannitol: review article. Ren Fail. 2014; 36(7): 1169-1176. Go to original source... Go to PubMed...
  42. Linkermann A, Heller JO, Prókai A, et al. The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol. 2013; 24(10): 1545-1557. Go to original source... Go to PubMed...
  43. Loh AH, Cohen AH. Drug-induced kidney disease-pathology and current concepts. Ann Acad Med Singapore. 2009; 38(3): 240-250. Go to original source...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.